Evidence map›Paper›PMID 31623580›Full record

ArticleBMC cancer2019

Case report of oxalate nephropathy in a patient with pancreatic metastases from renal carcinoma.

Karin Purshouse, Sarah Chamberlain, Maria Soares, Mark Tuthill, Andrew Protheroe, David R Mole

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Karin PurshouseDepartment of Oncology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, UK.
Sarah ChamberlainDepartment of Oncology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, UK.
Maria SoaresDepartment of Cellular Pathology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK.
Mark TuthillDepartment of Oncology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, UK.
Andrew ProtheroeDepartment of Oncology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, UK.
David R MoleOxford Kidney Unit, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. david.mole@ndm.ox.ac.uk.ORCID http://orcid.org/0000-0002-0984-300X
Churchill Hospital · GBJohn Radcliffe Hospital · GB

Funding

Cancer Research UK 16016Department of Health RP-2015-06-004
6 · The paper itself

Abstract

backgroundPatients with metastatic renal carcinoma frequently have pre-existing renal impairment and not infrequently develop worsening renal function as a complication of their treatment. The presence of pancreatic metastases in patients with metastatic renal carcinoma, often confers a more favourable prognosis and as a consequence this patient group may be exposed to such treatments for more prolonged periods of time. However, the development of renal failure may also be a consequence of the cancer itself rather than its treatment. CASE PRESENTATION: We present an 84-year-old patient receiving the tyrosine kinase inhibitor (TKI) pazopanib for metastatic renal carcinoma who developed oxalate nephropathy as a consequence of pancreatic exocrine insufficiency resulting from pancreatic metastases.

conclusionsThis case demonstrates the importance of investigating unexpected toxicities and highlights the potential consequences of pancreatic insufficiency and its sequelae in patients with pancreatic metastases.

Indexed as

AcetatesAged, 80 and overCalcium CompoundsCarcinoma, Renal CellExocrine Pancreatic InsufficiencyGastrointestinal AgentsHumansIndazolesKidney Failure, ChronicKidney NeoplasmsMaleOxalatesPancreatic NeoplasmsPancrelipaseProtein Kinase InhibitorsPyrimidinesAcetatescalcium acetateCalcium CompoundsGastrointestinal AgentsIndazolesOxalatesPancrelipasepazopanibProtein Kinase InhibitorsPyrimidinesSulfonamidesOxalate nephropathyPancreatic metastasesRenal cancerRenal impairment

Identifiers

PMID31623580
PMCPMC6798420
OpenAlexW2980512449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.